Comparative Pharmacology
Head-to-head clinical analysis: NOVANTRONE versus TRABECTEDIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NOVANTRONE versus TRABECTEDIN.
NOVANTRONE vs TRABECTEDIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mitoxantrone is a synthetic anthracenedione derivative that intercalates with DNA and inhibits topoisomerase II, leading to DNA strand breaks and inhibition of DNA and RNA synthesis. It also disrupts DNA repair and replication, and has immunosuppressive effects through inhibition of B cell, T cell, and macrophage function.
Trabectedin binds to the minor groove of DNA, forming adducts that lead to DNA strand breaks and inhibition of transcription. It also affects the tumor microenvironment by modulating cytokine production and inhibiting activated macrophages.
12 mg/m2 IV over 5-15 minutes once daily on days 1-3 of a 28-day cycle, or as a single dose of 12-14 mg/m2 IV every 21 days. For acute nonlymphocytic leukemia, 12 mg/m2 IV daily for 3 days with cytarabine.
1.5 mg/m² intravenously over 24 hours every 3 weeks.
None Documented
None Documented
Clinical Note
moderateTrabectedin + Digoxin
"Trabectedin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateTrabectedin + Digitoxin
"Trabectedin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateTrabectedin + Deslanoside
"Trabectedin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateTrabectedin + Acetyldigitoxin
"Trabectedin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life: 23-215 hours (mean ~37 hours). The long half-life reflects extensive tissue distribution and slow elimination, allowing weekly dosing.
Terminal elimination half-life ranges from 26 to 40 hours (mean ~33 hours) in patients with normal hepatic function, allowing for a 3-weekly dosing interval.
Primarily hepatic (biliary/fecal) elimination: ~25% as unchanged drug and metabolites in feces over 5 days; renal excretion accounts for ~11% (6-11%) as unchanged drug. Less than 10% excreted unchanged in urine.
Primarily fecal (approximately 58% of administered dose) with minor renal excretion (about 21% as unchanged drug and metabolites). Biliary excretion accounts for a significant portion of elimination via feces.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent